{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:50:58Z","timestamp":1776743458805,"version":"3.51.2"},"reference-count":19,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.clinthera.2012.08.006","type":"journal-article","created":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T05:48:12Z","timestamp":1346478492000},"page":"1986-1998","source":"Crossref","is-referenced-by-count":24,"title":["Evaluation of the Pharmacokinetics, Food Effect, Pharmacodynamics, and Tolerability of DA-1229, a Dipeptidyl Peptidase IV Inhibitor, in Healthy Volunteers: First-in-Human Study"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct00961025","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Tae-Eun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoung Soo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Kyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seo-Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo-Youn","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Goo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.08.006_bib1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.08.006_bib2","first-page":"S62","article-title":"Diagnosis and classification of diabetes mellitus","volume":"32","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2012.08.006_bib3","series-title":"Robbins and Cotran Pathologic Basis of Disease","article-title":"The Endocrine System","year":"2005"},{"key":"10.1016\/j.clinthera.2012.08.006_bib4","first-page":"528","article-title":"Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs","volume":"110","author":"Freeman","year":"2010","journal-title":"J Am Osteopath Assoc"},{"key":"10.1016\/j.clinthera.2012.08.006_bib5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.beem.2007.07.005","article-title":"DPP-4 inhibitors","volume":"21","author":"Ahren","year":"2007","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2012.08.006_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.lfs.2011.10.007","article-title":"DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes","volume":"90","author":"Kim","year":"2012","journal-title":"Life Sci"},{"key":"10.1016\/j.clinthera.2012.08.006_bib7","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1016\/j.bmcl.2011.04.029","article-title":"Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes","volume":"21","author":"Kim","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.clinthera.2012.08.006_bib10","series-title":"Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications","year":"2011"},{"key":"10.1016\/j.clinthera.2012.08.006_bib11","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1023\/A:1026451721686","article-title":"Confidence interval criteria for assessment of dose proportionality","volume":"17","author":"Smith","year":"2000","journal-title":"Pharm Res"},{"key":"10.1016\/j.clinthera.2012.08.006_bib12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1540-8167.2006.00408.x","article-title":"QT interval: how to measure it and what is \u201cnormal.\u201d","volume":"17","author":"Goldenberg","year":"2006","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.clinthera.2012.08.006_bib13","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1463-1326.2010.01212.x","article-title":"Pharmacokinetics of dipeptidylpeptidase-4 inhibitors","volume":"12","author":"Scheen","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2012.08.006_bib14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1517\/14656566.2012.642866","article-title":"A review of gliptins in 2011","volume":"13","author":"Scheen","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2012.08.006_bib15","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/0091270009337511","article-title":"A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects","volume":"49","author":"Bloomfield","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.08.006_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2125.2011.03931.x","article-title":"The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses","volume":"72","author":"Ring","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.08.006_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF00581038","article-title":"Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects","volume":"32","author":"Qualmann","year":"1995","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.clinthera.2012.08.006_bib18","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/BF00401846","article-title":"Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers","volume":"38","author":"Ritzel","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2012.08.006_bib19","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.clpt.2005.09.002","article-title":"Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses","volume":"78","author":"Herman","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2012.08.006_bib20","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.clinthera.2008.10.013","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study","volume":"30","author":"Lim","year":"2008","journal-title":"Clin Ther"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2012.08.006_bib21","first-page":"A82","article-title":"The DP-IV inhibitor MK-043 enhances active GLP-1 and reduces glucose following an OGTT in type 2 diabetics","volume":"52","author":"Herman","year":"2004","journal-title":"Diabetes"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812004870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812004870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T04:03:28Z","timestamp":1542773008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812004870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0149291812004870"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.08.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}